Heart failure & cardiomyopathies
The Peptide Neuromedin U (NMU) is Elevated in NYHA II and III Heart Failure
Authors' conclusion
NMU is elevated in serum from stage II and III heart failure patients, supporting data from our pre-heart failure animal model
Study context
- Population
- Patients with NYHA stage II and III HF, Royal Papworth Hospital, Cambridge UK24 HF serum samples
- Comparison
- HF patients vs healthy donors
- HFn = 24
- Outcome
- Serum NMU concentration (selective NMU-ELISA)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Serum NMU
P = 0.0007
Observational data: associations, not effects.
Further findings
Serum NMU by NYHA stage · no significant difference; unpaired Student's t-test
P = 0.85
Correlation of mean right atrial pressure with serum NMU
- Only mean right atrial pressure significantly correlated with serum NMU (regression analysis)
- R = 0.81, P < 0.00001
Original publication
The Peptide Neuromedin U (NMU) is Elevated in NYHA II and III Heart Failure. ESC Heart Fail. Published 5 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →